LISTA LUCRARI PUBLICATE BLOANCA-PRODAN MIHAELA

1. Toma, A.-O.; **Prodan, M**.; Reddyreddy, A.R.; Seclaman, E.; Crainiceanu, Z.; Bloanca, V.; Bratosin, F.; Dumitru, C.; Pilut, C.N.; Alambaram, S.; et al. The Epidemiology of Malignant Melanoma during the First Two Years of the COVID-19 Pandemic: A Systematic Review. Int. J. Environ. Res. Public Health 2023, 20, 305. <https://doi.org/10.3390/ijerph20010305> - PubMed Indexed.
2. Bota, A.V.; Bratosin, F.; Bandi, S.S.S.; Bogdan, I.; Razvan, D.V.; Toma, A.-O.; Indries, M.F.; Csep, A.N.; Cotoraci, C.; **Prodan, M.;** et al. A Comparative Analysis of Liver Injury Markers in Post-COVID Syndrome among Elderly Patients: A Prospective Study. J. Clin. Med. 2024, 13, 1149. <https://doi.org/10.3390/jcm13041149>. IF 3.9
3. Sukosd, I.E.; Gadde, S.T.; Pravallika, M.; Pescariu, S.A.; **Prodan, M**.; Toma, A.-O.; Fericean, R.M.; Hrubaru, I.; Sarau, O.S.; Fira-Mladinescu, O. Evaluating the Health-Related Quality of Life in Patients with COPD and Chronic Heart Failure Post-Hospitalization after COVID-19 Using the EQ-5D and KCCQ Questionnaires. Diseases 2024, 12, 124. <https://doi.org/10.3390/diseases12060124>. IF 3.7
4. **Prodan, M**.; Costescu, S.; Elagez, A.; Laitin, S.M.D.; Bloanca, V.; Crainiceanu, Z.; Seclaman, E.; Toma, A.-O.; Fericean, R.M.; Puenea, G.; et al. Molecular Markers in Melanoma Progression: A Study on the Expression of miRNA Gene Subtypes in Tumoral vs. Benign Nevi. Curr. Oncol. 2024, 31, 2881-2894. <https://doi.org/10.3390/curroncol31050220>. IF 2.6
5. Daniluc, R.-I.; Craina, M.; Thakur, B.R.; **Prodan, M**.; Bratu, M.L.; Daescu, A.-M.C.; Puenea, G.; Niculescu, B.; Negrean, R.A. Comparing Relationship Satisfaction and Body-Image-Related Quality of Life in Pregnant Women with Planned and Unplanned Pregnancies. Diseases 2024, 12, 109. <https://doi.org/10.3390/diseases12060109>. IF 3.7
6. Pantea, M.; Iacob, D.; Bortea, C.I.; Enatescu, I.; Barbos, V.; **Prodan, M**.; Tudor, R.; Cozma, G.V. Predictive Role of NLR, dNLR, PLR, NLPR, and Other Laboratory Markers in Diagnosing SIRS in Premature Newborns. Clin. Pract. 2024, 14, 1065-1075. <https://doi.org/10.3390/clinpract14030084>. IF 2.3
7. Costescu, O.C.; Manea, A.M.; Boia, E.R.; Cioboata, D.M.; Doandes, F.M.; Enatescu, I.; Costescu, S.; **Prodan, M**.; Boia, M. Early Postnatal Administration of Erythropoietin and Its Association with Neurodevelopmental Outcomes and Incidence of Intraventricular Hemorrhage and Hypoxic-Ischemic Encephalopathy: A Four-Week Observational Study. Pediatr. Rep. 2024, 16, 339-352. <https://doi.org/10.3390/pediatric16020030>. IF 1.1
8. Pantea, M.; Iacob, D.; Dima, M.; **Prodan, M**.; Belei, O.; Negrean, R.A.; Ilie, A.C. Predictive Value of Inflammatory Markers NLR, PLR, APRI, SII, and Liver Function Tests in Systemic Inflammatory Response Syndrome Detection in Full-Term Newborns. Children 2024, 11, 593. <https://doi.org/10.3390/children11050593>. IF 2.4.
9. **Prodan M**, Crainceanu ZP. Pushing the boundaries – bone grafting in hand trauma – a case report. Acta Medica Transilvanica December 27 (4): 59-61. Online ISSN 2285-7079 – BDI.